Background: We evaluated the diagnostic performance of the FilmArray Blood Culture Identification Panel (BCID; bioMerieux) for the detection of bloodstream pathogens.
Methods: From May to August 2022, up to 67 samples from positive blood cultures previously processed with BACTEC FX (BD) were collected and submitted to the BCID panel. BCID panel results were compared with traditional culture results.
Results: We tested 67 positive blood culture samples; 13 samples were from pediatric bottles of BACTEC Peds Plus/F media (BD). The overall sensitivity of the BCID panel was 89.9% (62/69; 95% CI, 80.2 - 95.3%). For blood-stream pathogens targeted by the BCID panel, sensitivity was 98.4% (62/63; 95% CI, 90.7 - > 99.9%). Interestingly, Proteus species were additionally detected in 6 samples from pediatric blood culture bottles.
Conclusions: BCID demonstrated high clinical sensitivity for target pathogens, but positive findings for unexpected multiple targets or Proteus species require cautious interpretation to avoid false positives.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2023.231133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the QIAstat-Dx BCID GN and GPF kits for direct identification and antimicrobial resistance prediction from blood culture bottles.
J Clin Microbiol
December 2024
Department of Laboratory Medicine, National University Hospital, , Singapore.
Article Synopsis
- * The study analyzed a total of 174 monomicrobial blood cultures, finding that the majority of targeted Gram-negative and all Gram-positive organisms were successfully identified, demonstrating high sensitivity and specificity for detecting specific resistance mechanisms.
- * Overall, the QIAstat-Dx kits showed strong correlation in both pathogen identification and predicting β-lactam resistance, marking significant progress in rapid diagnostic methods for blood infections.
Impact of rapid blood culture identification PCR panel on optimal antibiotic use in methicillin-susceptible bacteremia.
Microbiol Spectr
October 2024
Department of Medicine, Morristown Medical Center, Morristown, New Jersey, USA.
Unlabelled: Rapid identification of methicillin-susceptible (MSSA) bacteremia may optimize antibiotic use and clinical outcomes. The study objective was to assess the impact of the BioFire® blood culture identification (BCID) polymerase chain reaction (PCR) panel on antibiotic use and clinical outcomes in patients with MSSA bacteremia. This was a retrospective chart review of adult inpatients with MSSA bacteremia during the pre-PCR (June 2018-December 2019) and post-PCR (June 2020-December 2021) implementation periods.
View Article and Find Full Text PDFEvaluation of an expanded antibiotic resistance gene panel on prediction of antimicrobial susceptibility results for Gram-negative bacteria in blood cultures.
J Clin Microbiol
October 2024
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Unlabelled: The QIAstat-Dx BCID Panels (RUO) ("QIAstat," QIAGEN, Hilden, Germany) for identification of 13 Gram-negative bacteria and 18 antimicrobial resistance (AMR) gene groups was evaluated. The study was conducted in two phases; in phase 1, analytical performance was evaluated against 154 challenge isolates against whole genome sequencing data. In this phase, sensitivity and specificity of organism identification calls were 153/154 (99.
View Article and Find Full Text PDFGetting rapid diagnostic test data into the appropriate hands by leveraging pharmacy staff and a clinical surveillance platform: a case study from a US community hospital.
J Antimicrob Chemother
September 2024
bioMérieux Global Medical Affairs Microbiology, bioMérieux, Marcy-l'Étoile, France.
Objectives: To outline the procedural implementation and optimization of rapid diagnostic test (RDT) results for bloodstream infections (BSIs) and to evaluate the combination of RDTs with real-time antimicrobial stewardship team (AST) support plus clinical surveillance platform (CSP) software on time to appropriate therapy in BSIs at a single health system.
Methods: Blood culture reporting and communication were reported for four time periods: (i) a pre-BCID [BioFire® FilmArray® Blood Culture Identification (BCID) Panel] implementation period that consisted of literature review and blood culture notification procedure revision; (ii) a BCID implementation period that consisted of BCID implementation, real-time results notification via CSP, and creation of a treatment algorithm; (iii) a post-BCID implementation period; and (iv) a BCID2 implementation period. Time to appropriate therapy metrics was reported for the BCID2 time period.
Impact of BioFire® Blood Culture Identification (BCID) panels on antibiotic management of bacteremia due to select organisms.
Diagn Microbiol Infect Dis
September 2024
Morristown Medical Center, 100 Madison Avenue, Morristown, NJ 07960, United States.
Article Synopsis
- - The study evaluated the impact of the BioFire® FilmArray® blood culture identification panels on the time to optimal therapy (TTOT) for bacteremia caused by specific organisms at two community hospitals.
- - Results showed no significant differences in overall TTOT between groups before and after implementing the BCID panels, but BCID2 saw more timely therapy adjustments and effective carbapenem use for gram-negative bacteria.
- - There was also a notable decrease in the length of vancomycin treatment for gram-positive bacteria after BCID2 was implemented, indicating improved antimicrobial prescribing practices.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!